Introgen Licenses Patents From M.D. Anderson

Austin, Texas-based Introgen Therapeutics has licensed a portfolio of patents from The University of Texas M. D. Anderson Cancer Center, the firm reported this week. The patents cover technology for the delivery of biologically active proteins, polypeptides and peptides using novel nanoparticle delivery complexes. Financial terms of the license were not disclosed. Introgen is developing biopharmaceuticals for the treatment of cancer and other diseases.